Page 74 - Quest Diagnostics News Today

MRD (Minimal Residual Disease) Testing Market Analysis and Future Prospects for 2030

Westpac Banking Corp lowered its stake in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 73.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,334 shares of the medical research company’s stock after selling 60,289 shares during the quarter. Westpac Banking Corp’s […]

Today we're going to take a look at the well-established Quest Diagnostics Incorporated ( NYSE:DGX ). The company's...

15.11.2023 - NORTHAMPTON, MA / ACCESSWIRE / November 15, 2023 / Quest DiagnosticsOriginally published in Quest Diagnostics Corporate Responsibility Report 2022Our global suppliers play a significant role in enabling us to deliver safe and high-quality services ...

Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) announced a quarterly dividend on Monday, November 13th, RTT News reports. Investors of record on Wednesday, January 17th will be given a dividend of 0.71 per share by the medical research company on Wednesday, January 31st. This represents a $2.84 dividend on an annualized basis and a […]

/PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the worlds leading provider of diagnostic information services, today announced that its Board of Directors...

Anatomic Pathology IndustryThrough the analysis of tissue samples to recognise and comprehend distinct pathological situations, the field of anatomic pathology plays a significant role in the diagnosis and treatment of disease. The global Anatomic Pathology Industry has shown significant growth and development due t...

Investors are seeing some big reactions to earnings results in tech and have a few reasons to think some beaten-up names might be finding their footing.

Quest Diagnostics (NYSE:DGX – Free Report) had its target price hoisted by Piper Sandler from $130.00 to $140.00 in a report released on Monday, Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock. Several other equities research analysts also recently issued reports on DGX. Morgan Stanley restated an equal […]

Following the CervicalCheck scandal, major reform was needed in how Irish slides are treated, including less reliance on labs in the US for testing. We look at the recent reopening of the Coombe laboratory and at how the screening process has changed in recent years